HomeProductsBioactive CompoundsNeuronal SignalingSecretaseCrenigacestat
Chemical structure of CAS 1421438-81-4

Crenigacestat

CAS No.1421438-81-4
MDL No.MFCD26142650
MFC22H23F3N4O4
MW464.40
InChI KeyYCBAQKQAINQRFW-UGSOOPFHSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Crenigacestat (LY3039478) is an orally active inhibitor of Notch and γ-secretase, with an IC50 of 1 nM in most tested tumor cell lines.

CAS No.1421438-81-4
Product NameCrenigacestat

Associated Conditions

neoplasm·multiple myeloma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Notch1-mediated histone demethylation of HCN4 contributes to aconitine-induced ventricular myocardial dysrhythmia.

Toxicology letters • Vol. 327 • 2020
PMID: 32234357DOI: 10.1016/j.toxlet.2020.03.017

Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.

Cell death and differentiation • Vol. 27, Issue 8 • 2020
PMID: 32042099PMC: PMC7370218DOI: 10.1038/s41418-020-0505-4

Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.

Journal of experimental & clinical cancer research : CR • Vol. 38, Issue 1 • 2019
PMID: 31307525PMC: PMC6631946DOI: 10.1186/s13046-019-1295-8

Inhibition of notch pathway signaling: a one compound mission to treat cancer.

ACS medicinal chemistry letters • Vol. 4, Issue 4 • 2013
PMID: 24900678PMC: PMC4027576DOI: 10.1021/ml400057c

Documentation

Similar Products